Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Perez-Gracia JL, Mellado B, Hansen AR, Alonso-Gordoa T, Gomez-Roca C, Løvendahl Eefsen R, Negrier S, Suárez C, Lee JL, Hussain A, Pedrazzoli P, Moreno V, Rodriguez-Vida A, Sosman JA, Waddell T, Bedke J, Park SH, Sznol M, Spychaj L, Andersson E, Julien-Laferriere A, Cheng WY, Watson C, Silva AP, Heichinger C, Staedler N, Sleiman N, Dejardin D, Boetsch C, Evers S, Vardar T, Ardeshir-Tandon C, Dorado Pérez J, Charo J, Keshelava N, Kraxner A, Teichgräber V, Powles T

Open source

DOI: 10.1136/jitc-2025-012466
Published: 2026 Apr 9
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2025-012466,
  title = {Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.},
  author = {Perez-Gracia JL and Mellado B and Hansen AR and Alonso-Gordoa T and Gomez-Roca C and Løvendahl Eefsen R and Negrier S and Suárez C and Lee JL and Hussain A and Pedrazzoli P and Moreno V and Rodriguez-Vida A and Sosman JA and Waddell T and Bedke J and Park SH and Sznol M and Spychaj L and Andersson E and Julien-Laferriere A and Cheng WY and Watson C and Silva AP and Heichinger C and Staedler N and Sleiman N and Dejardin D and Boetsch C and Evers S and Vardar T and Ardeshir-Tandon C and Dorado Pérez J and Charo J and Keshelava N and Kraxner A and Teichgräber V and Powles T},
  year = {2026},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2025-012466},
  url = {https://doi.org/10.1136/jitc-2025-012466}
}

RIS

TY  - JOUR
TI  - Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
AU  - Perez-Gracia JL
AU  - Mellado B
AU  - Hansen AR
AU  - Alonso-Gordoa T
AU  - Gomez-Roca C
AU  - Løvendahl Eefsen R
AU  - Negrier S
AU  - Suárez C
AU  - Lee JL
AU  - Hussain A
AU  - Pedrazzoli P
AU  - Moreno V
AU  - Rodriguez-Vida A
AU  - Sosman JA
AU  - Waddell T
AU  - Bedke J
AU  - Park SH
AU  - Sznol M
AU  - Spychaj L
AU  - Andersson E
AU  - Julien-Laferriere A
AU  - Cheng WY
AU  - Watson C
AU  - Silva AP
AU  - Heichinger C
AU  - Staedler N
AU  - Sleiman N
AU  - Dejardin D
AU  - Boetsch C
AU  - Evers S
AU  - Vardar T
AU  - Ardeshir-Tandon C
AU  - Dorado Pérez J
AU  - Charo J
AU  - Keshelava N
AU  - Kraxner A
AU  - Teichgräber V
AU  - Powles T
PY  - 2026
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2025-012466
UR  - https://doi.org/10.1136/jitc-2025-012466
ER  -

APA

JL, P., B, M., AR, H., T, A., C, G., R, L. E., S, N., C, S., JL, L., A, H., P, P., V, M., A, R., JA, S., T, W., J, B., SH, P., M, S., L, S., E, A., A, J., WY, C., C, W., AP, S., C, H., N, S., N, S., D, D., C, B., S, E., T, V., C, A., J, D. P., J, C., N, K., A, K., V, T., & T, P. (2026). Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-012466

Source records

pubmed · retrieved 2026-09-27T15:29:51.194Z